ArticleBMC pharmacology & toxicology2025
Modified diatom-based ocular suspension for sustained diclofenac sodium delivery: a novel drug carrier approach.
Article in BMC pharmacology & toxicology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. An erratum has been issued. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
- Erratum issued
Authors and funding
3 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
purposeOphthalmic drugs typically last only around 15 minutes due to rapid elimination from tear flow, with only about 2% absorption, while the rest may enter the nasal mucosa, potentially causing systemic side effects. Diatoms, with properties like unique structure, abundance, low cost, heat resistance, non-toxicity, and easy access, present a promising solution for sustained drug delivery. This study aimed to prepare and evaluate an ocular suspension of diclofenac sodium loaded onto modified diatoms.
methodsDiatoms were modified with aluminum sulfate solution, followed by loading of diclofenac sodium. Characteristics of diatoms before and after modification-particle size, surface charge, and drug loading-were analyzed using electron microscopy, FTIR (Fourier Transform Infrared Spectroscopy), XRD (X-ray Diffraction), and elemental mapping. BET (Brunauer-Emmett-Teller (Surface Area Analysis) testing provided adsorption data, while DSC (Differential Scanning Calorimetry) assessed thermal properties. An in vitro release study using a dialysis bag in artificial tear fluid examined drug release over 8 hours. Drug content was determined by spectrophotometry, and cytotoxicity on MDA-MB-231 and HEP-G2 cell lines was evaluated at different diatom concentrations.
resultsSEM (Scanning Electron Microscopy) imaging showed no topographic changes post-modification. BET and XRD analyses confirmed drug loading and structural stability, while FTIR indicated involvement of carboxylate groups. TGA and DSC showed stable thermal properties. Elemental mapping confirmed increased surface elements and high drug loading. Modified diatoms showed sustained drug release and no significant cytotoxicity differences.
conclusionModified diatoms demonstrated higher drug loading and sustained release, indicating their potential for safe and effective ocular drug delivery. Further studies are recommended to confirm these findings.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.